MedinCell gains over 9% in Paris, helped by an analysis from Oddo, which maintains its 'outperform' rating on the stock, with a price target raised from 11 to 14 euros.

With the FDA expected back in the next few weeks (Q2 2023), the approval followed by the commercial launch of Uzedy (mdc-MRI) are the main catalysts for the stock in the short term, believes the research firm.

In Oddo's view, this will mark MedinCell's transition from an R&D biotech to a commercial company, but will also make its BEPO platform all the more credible for securing new partnerships.

Finally, in addition to the approval of Uzedy, MedinCells' newsflow over the coming months should be marked by the clinical progress of its two other assets, mdcCWM (celecoxib) for the management of post-operative pain, and mdcTJK (olanzapine) in schizophrenia.

"We expect Phase III results in late 2023 and Q3/Q4 2024 respectively", concludes the analyst.

Copyright (c) 2023 CercleFinance.com. All rights reserved.